Immunogenicity and Neutralizing Activity Comparison of SARS-CoV-2 Spike Full-Length and Subunit Domain Proteins in Young Adult and Old-Aged Mice

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to be expanding the pandemic disease across the globe. Although SARS-CoV-2 vaccines were rapidly developed and approved for emergency use of vaccination in humans, supply and production difficulties are slowing down the global va...

Full description

Bibliographic Details
Published in:	Vaccines
Main Authors:	Ki-Hye Kim, Noopur Bhatnagar, Subbiah Jeeva, Judy Oh, Bo Ryoung Park, Chong Hyun Shin, Bao-Zhong Wang, Sang-Moo Kang
Format:	Article
Language:	English
Published:	MDPI AG 2021-03-01
Subjects:	SARS-CoV-2 spike neutralizing activity RBD-hACE2 inhibition cellular immunity aged mice
Online Access:	https://www.mdpi.com/2076-393X/9/4/316

Similar Items

Role of tannic acid against SARS-cov-2 cell entry by targeting the interface region between S-protein-RBD and human ACE2
by: Xi Chen, et al.
Published: (2022-08-01)

Surface charge changes in spike RBD mutations of SARS-CoV-2 and its variant strains alter the virus evasiveness via HSPGs: A review and mechanistic hypothesis
by: Zhongyun Zhang, et al.
Published: (2022-08-01)

Mass Spectrometry Analysis of Newly Emerging Coronavirus HCoV-19 Spike Protein and Human ACE2 Reveals Camouflaging Glycans and Unique Post-Translational Modifications
by: Zeyu Sun, et al.
Published: (2021-10-01)

SARS-CoV-2 tetrameric RBD protein blocks viral infection and induces potent neutralizing antibody response
by: Zheng Liu, et al.
Published: (2022-10-01)

Intranasal Liposomal Formulation of Spike Protein Adjuvanted with CpG Protects and Boosts Heterologous Immunity of hACE2 Transgenic Mice to SARS-CoV-2 Infection
by: Momtchilo Russo, et al.
Published: (2023-11-01)

A Suitable Membrane Distance Regulated by the RBD_ACE2 Interaction is Critical for SARS‐CoV‐2 Spike‐Mediated Viral Invasion
by: Mengdan Wu, et al.
Published: (2023-10-01)

Deep Structural Analysis of Myriads of Omicron Sub-Variants Revealed Hotspot for Vaccine Escape Immunity
by: Valeria Gerardi, et al.
Published: (2023-03-01)

Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes
by: Debashree Chatterjee, et al.
Published: (2022-01-01)

Phage Display-Derived Compounds Displace hACE2 from Its Complex with SARS-CoV-2 Spike Protein
by: Marc Sevenich, et al.
Published: (2022-02-01)

Identification of Surface Glycoprotein Mutations of SARS-CoV-2 in Isolated Strains from Iraq
by: Ali A. Dawood, et al.
Published: (2022-07-01)

Coronil effectively inhibits the interaction of clinically relevant Omicron mutants of SARS-CoV-2 spike proteins with human ACE2 receptor
by: Acharya Balkrishna, et al.
Published: (2025-02-01)

Immunogenicity and protection efficacy of a COVID-19 DNA vaccine encoding spike protein with D614G mutation and optimization of large-scale DNA vaccine production
by: Aytül Gül, et al.
Published: (2024-06-01)

Immunogenicity and Protectivity of Sputnik V Vaccine in hACE2-Transgenic Mice against Homologous and Heterologous SARS-CoV-2 Lineages Including Far-Distanced Omicron BA.5
by: Inna V. Dolzhikova, et al.
Published: (2024-10-01)

Clinical and experimental evidence suggest omicron variant of SARS-CoV-2 is inherently less pathogenic than delta variant independent of previous immunity
by: Ramachandran Thiruvengadam, et al.
Published: (2023-10-01)

Comparison of Six Serological Immunoassays for the Detection of SARS-CoV-2 Neutralizing Antibody Levels in the Vaccinated Population
by: Hee-Jung Lee, et al.
Published: (2022-04-01)

Glycyrrhizin Inhibits SARS-CoV-2 Entry into Cells by Targeting ACE2
by: Ming-Feng He, et al.
Published: (2022-10-01)

VSV-ΔG-Spike Candidate Vaccine Induces Protective Immunity and Protects K18-hACE2 Mice against SARS-CoV-2 Variants
by: Yfat Yahalom-Ronen, et al.
Published: (2023-06-01)

K18- and CAG-hACE2 Transgenic Mouse Models and SARS-CoV-2: Implications for Neurodegeneration Research
by: Simona Dedoni, et al.
Published: (2022-06-01)

Premature aging effects on COVID-19 pathogenesis: new insights from mouse models
by: Wu Haoyu, et al.
Published: (2024-08-01)

Single MVA-SARS-2-ST/N Vaccination Rapidly Protects K18-hACE2 Mice against a Lethal SARS-CoV-2 Challenge Infection
by: Sabrina Clever, et al.
Published: (2024-03-01)

The protection of CoronaVac against the infection of wild‐type SARS‐CoV‐2 (WH‐09) or Omicron variant in nude‐hACE2 mice
by: Kaili Lin, et al.
Published: (2023-08-01)

Subtle Changes at the RBD/hACE2 Interface During SARS-CoV-2 Variant Evolution: A Molecular Dynamics Study
by: Aria Gheeraert, et al.
Published: (2025-04-01)

Editorial: Interaction and dynamics of biological molecules
by: Mohana Priya Arumugam, et al.
Published: (2024-07-01)

Protection of K18-hACE2 Mice against SARS-CoV-2 Challenge by a Capsid Virus-like Particle-Based Vaccine
by: Sebenzile K. Myeni, et al.
Published: (2024-07-01)

Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants
by: Tasnim Saifudin Zakir, et al.
Published: (2022-01-01)

Identification of potential SARS-CoV-2 entry inhibitors by targeting the interface region between the spike RBD and human ACE2
by: Arun Bahadur Gurung, et al.
Published: (2021-02-01)

Prolonged Protective Immunity Induced by Mild SARS-CoV-2 Infection of K18-hACE2 Mice
by: Liat Bar-On, et al.
Published: (2022-04-01)

Receptor-Binding Domain (RBD) Antibodies Contribute More to SARS-CoV-2 Neutralization When Target Cells Express High Levels of ACE2
by: Ariana Ghez Farrell, et al.
Published: (2022-09-01)

Evaluating the Spike–hACE2 interactions in the wild type and variants of concern of SARS -CoV-2 at different temperatures
by: Nabanita Mandal, et al.
Published: (2024-01-01)

Structural insights into hybridoma-derived neutralizing monoclonal antibodies against Omicron BA.5 and XBB.1.16 variants of SARS-CoV-2
by: Hengrui Hu, et al.
Published: (2025-02-01)

Neuroinvasion and Encephalitis Following Intranasal Inoculation of SARS-CoV-2 in K18-hACE2 Mice
by: Pratima Kumari, et al.
Published: (2021-01-01)

SARS-CoV-2 Infects Primary Neurons from Human ACE2 Expressing Mice and Upregulates Genes Involved in the Inflammatory and Necroptotic Pathways
by: Hussin A. Rothan, et al.
Published: (2022-02-01)

Towards Quantum-Chemical Level Calculations of SARS-CoV-2 Spike Protein Variants of Concern by First Principles Density Functional Theory
by: Wai-Yim Ching, et al.
Published: (2023-02-01)

Chemiluminescence Immunoassay Based Serological Immunoassays for Detection of SARS-CoV-2 Neutralizing Antibodies in COVID-19 Convalescent Patients and Vaccinated Population
by: Qiangling Yin, et al.
Published: (2021-07-01)

Multivalent and Sequential Heterologous Spike Protein Vaccinations Effectively Induce Protective Humoral Immunity against SARS-CoV-2 Variants
by: Rong Liu, et al.
Published: (2024-03-01)

The Development of Pharmacophore Models for the Search of New Natural Inhibitors of SARS-CoV-2 Spike RBD–ACE2 Binding Interface
by: Valentin A. Semenov, et al.
Published: (2022-12-01)

Severe Acute Respiratory Syndrome Coronavirus 2 Receptor (Human Angiotensin-Converting Enzyme 2) Binding Inhibition Assay: A Rapid, High-Throughput Assay Useful for Vaccine Immunogenicity Evaluation
by: Joyce S. Plested, et al.
Published: (2023-02-01)

Investigation of COVID-19 virus mutagenicity and the effect of the NSP13, NSP14, and NSP16 on the -1 ribosomal frameshifting
by: Ali Khanifar, et al.
Published: (2024-07-01)

Induction of Potent and Durable Neutralizing Antibodies Against SARS-CoV-2 Using a Receptor Binding Domain-Based Immunogen
by: Vikram Srivastava, et al.
Published: (2021-03-01)

A siRNA targets and inhibits a broad range of SARS‐CoV‐2 infections including Delta variant
by: Yi‐Chung Chang, et al.
Published: (2022-02-01)